日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition

胃肠道肿瘤免疫编辑和免疫检查点抑制抵抗中的表观遗传启动子改变

Raghav Sundar, Kie-Kyon Huang #, Vikrant Kumar #, Kalpana Ramnarayanan #, Deniz Demircioglu #, Zhisheng Her #, Xuewen Ong, Zul Fazreen Bin Adam Isa, Manjie Xing, Angie Lay-Keng Tan, David Wai Meng Tai, Su Pin Choo, Weiwei Zhai, Jia Qi Lim, Meghna Das Thakur, Luciana Molinero, Edward Cha, Marcella Fa

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

FGF401 以及 FGF401 与 spartalizumab 联合治疗肝细胞癌或生物标志物选定的实体瘤患者的首次人体 1/2 期研究

Stephen L Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X Zhu, Thomas Yau, Ho Yeon

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

PRL3-zumab 作为免疫疗法抑制表达 PRL3 癌蛋白的肿瘤

Min Thura #, Abdul Qader Al-Aidaroos #, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne Ngeow, M

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

胆管癌不同病因亚型的全基因组和表观基因组图谱

Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng, Su Pin Choo, Swe Swe Myint, Raynoo Thanan, Sanjanaa Nagarajan, Weng Khong Lim, Cedric Chuan Young Ng, Arnoud Boot, Mo Liu, Choon Kiat Ong